BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 15915011)

  • 1. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
    Tomlinson HS; Corlett SA; Allen MB; Chrystyn H
    Br J Clin Pharmacol; 2005 Dec; 60(6):605-10. PubMed ID: 16305584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Techniques of assessing small airways dysfunction.
    McNulty W; Usmani OS
    Eur Clin Respir J; 2014; 1():. PubMed ID: 26557240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    Hendeles L; Colice GL; Meyer RJ
    N Engl J Med; 2007 Mar; 356(13):1344-51. PubMed ID: 17392304
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting inhaled beta 2-agonists and the loss of "bronchoprotective" efficacy.
    Abisheganaden J; Boushey HA
    Am J Med; 1998 May; 104(5):494-7. PubMed ID: 9626035
    [No Abstract]   [Full Text] [Related]  

  • 12. The rejuvenated pressurised metered dose inhaler.
    Bell J; Newman S
    Expert Opin Drug Deliv; 2007 May; 4(3):215-34. PubMed ID: 17489650
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.